Patrice X. Petit | Signal Transduction | Best Researcher Award

Dr. Patrice X. Petit | signal transduction | Best Researcher Award

 Research director | Centre National de la Recherche Scientifique | France

Dr. Patrice X. Petit, Doctor ès Sciences and PhD in Biology, is a Research Director at the French National Centre for Scientific Research (CNRS), where he has served since 1979 and established an internationally recognized career in cell biology. Trained at the Université Pierre et Marie Curie and the Université Denis Diderot (Paris), his work has focused on the molecular mechanisms governing cell death, mitochondrial dynamics, oxidative stress, and their implications in cancer biology, immunology, and toxicology. Over more than four decades, he has developed a broad international scientific presence through extensive teaching and research collaborations across Europe, North America, and Asia, including academic engagements with institutions such as the Chinese Academy of Sciences, Caltech, UT Southwestern, the Beatson Cancer Research Center in Glasgow, the University of Madrid, and multiple leading universities throughout Scandinavia, Germany, and France. His scientific leadership is further reflected in his service as an elected member (2016–2020) of the Scientific Council of the CNRS Institute of Biological Sciences (INSB). Dr. Petit has authored 134 scientific publications, accumulating approximately 12,500 citations and an h-index of 44, demonstrating sustained research influence across several biomedical domains, including contributions to plant biology. He is an active peer reviewer for major journals such as Cancer Research, Journal of Cell Biology, PNAS, Oncogene, and Cell Death and Differentiation, and he has served as a grant reviewer for major funding bodies, including the Austrian Academy of Sciences, the French National Research Agency (ANR), EMBO, the Swiss National Science Foundation, and the Fondation pour la Recherche Médicale. His interdisciplinary background—ranging from a formal qualification in history (Université Paris Diderot, 1979) to a DIU in rare diseases (Université de Strasbourg, 2017)—underscores both scientific depth and broader intellectual engagement. Through his sustained research output, international collaborations, and service to the scientific community, Patrice X. Petit has contributed significantly to advancing fundamental and translational knowledge in cell biology, with measurable societal impact across biomedical research and education.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

Zamzami, N., Marchetti, P., Castedo, M., Decaudin, D., Macho, A., Hirsch, T., … Petit, P. X. (1995). Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. The Journal of Experimental Medicine, 182(2), 367–377.

Zamzami, N., Marchetti, P., Castedo, M., Zanin, C., Vayssière, J. L., Petit, P. X., … Kroemer, G. (1995). Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. The Journal of Experimental Medicine, 181(5), 1661–1672.

Kroemer, G., Petit, P., Zamzami, N., Vayssière, J. L., & Mignotte, B. (1995). The biochemistry of programmed cell death. The FASEB Journal, 9(13), 1277–1287.

Petit, P. X., Lecoeur, H., Zorn, E., Dauguet, C., Mignotte, B., & Gougeon, M. L. (1995). Alterations in mitochondrial structure and function are early events of dexamethasone-induced thymocyte apoptosis. The Journal of Cell Biology, 130(1), 157–167.

Petit, P. X., Susin, S. A., Zamzami, N., Mignotte, B., & Kroemer, G. (1996). Mitochondria and programmed cell death: Back to the future. FEBS Letters, 396(1), 7–13.

Dr. Petit’s work has fundamentally advanced our understanding of mitochondrial biology and programmed cell death, shaping modern concepts of apoptosis, autophagy, and cellular stress responses. His discoveries enabled new biomedical approaches to cancer, immunology, and rare diseases

Cristina Solé | Biochemistry, Genetics and Molecular Biology | Women Researcher Award

Dr. Cristina Solé | Biochemistry, Genetics and Molecular Biology | Women Researcher Award

Investigadora Principal Sénior-Júnior at Vall Hebron Institut Research VHIR, Spain

Dr. Cristina Solé Marcé is a distinguished researcher specializing in systemic lupus erythematosus (SLE) with over a decade of experience in clinical-translational research. She holds dual degrees in Chemistry and Biochemistry, a PhD with international distinction, and a master’s in Synthesis and Catalysis from Universitat Rovira i Virgili. As a Senior-Junior Principal Investigator at Vall d’Hebron Research Institute, her work focuses on identifying novel biomarkers, developing personalized treatments, and exploring innovative therapies such as CAAR-T cells for lupus nephritis. She has published 31 scientific articles, with 94% as first, last, or corresponding author, and has collaborated with leading institutions, startups, and pharmaceutical companies. A recipient of the 2023 Health Science Award from the Institut d’Estudis Catalans, she is actively engaged in clinical trials, mentorship, and public science outreach. Dr. Solé’s contributions significantly advance lupus research, making her an outstanding candidate for the Women Researcher Award.

Professional Profile 

Education

Dr. Cristina Solé Marcé has a strong academic background in chemistry, biochemistry, and translational medicine. She earned dual degrees in Chemistry and Biochemistry from Universitat Rovira i Virgili, followed by a master’s in Synthesis and Catalysis at the same institution. She later pursued a PhD with international distinction, focusing on innovative research in systemic lupus erythematosus (SLE). Her doctoral work provided a solid foundation for her career in clinical and translational research, particularly in autoimmune diseases. Committed to continuous learning, Dr. Solé has engaged in specialized training programs, including those in biomarker discovery and personalized medicine. Her educational journey, complemented by interdisciplinary expertise and hands-on research, has positioned her as a leading scientist in lupus research. With extensive collaborations and contributions to high-impact publications, her academic achievements continue to shape advancements in precision medicine and novel therapeutic approaches for lupus and related autoimmune disorders.

Professional Experience

Dr. Cristina Solé Marcé is an accomplished researcher specializing in autoimmune diseases, particularly systemic lupus erythematosus (SLE). She has extensive experience in translational and clinical research, focusing on biomarker discovery and personalized medicine. Throughout her career, she has collaborated with leading research institutions and hospitals, contributing to the advancement of novel diagnostic and therapeutic strategies. Dr. Solé has played a key role in multidisciplinary research projects, integrating molecular biology, immunology, and clinical data to improve patient outcomes. She has also published extensively in high-impact scientific journals and presented her findings at international conferences. Her expertise extends to project management, mentorship of young researchers, and securing competitive research funding. Currently, she continues to drive innovation in lupus research, leveraging her knowledge in precision medicine to develop targeted treatments. Her work has had a significant impact on improving the understanding and management of autoimmune diseases worldwide.

Research Interest

Dr. Cristina Solé Marcé’s research interests focus on autoimmune diseases, with a particular emphasis on systemic lupus erythematosus (SLE). Her work explores the molecular mechanisms underlying disease pathogenesis, aiming to identify novel biomarkers for early diagnosis, prognosis, and treatment response. She is deeply involved in translational research, integrating clinical data with advanced molecular and immunological techniques to develop personalized therapeutic strategies. Dr. Solé is particularly interested in the role of epigenetics, gene expression, and immune system dysregulation in lupus and related disorders. Her research also extends to precision medicine approaches, seeking to tailor treatments to individual patients based on their genetic and molecular profiles. She collaborates with multidisciplinary teams, including clinicians, bioinformaticians, and immunologists, to translate laboratory discoveries into clinical applications. Through her work, Dr. Solé aims to enhance disease management and improve the quality of life for patients suffering from autoimmune conditions.

Award and Honor

Dr. Cristina Solé Marcé is a distinguished researcher specializing in autoimmune diseases, particularly systemic lupus erythematosus (SLE) and antiphospholipid syndrome. Since 2021, she has served as a Senior-Junior Principal Investigator in the Rheumatology team at the Systemic Lupus Erythematosus Unit of the Vall Hebron Research Institute (VHIR). Prior to this role, she dedicated six years as a postdoctoral researcher within the same unit. Her research endeavors focus on enhancing patient outcomes by identifying novel biomarkers to monitor disease status non-invasively and exploring the effects of new drugs and molecular pathways involved in various clinical manifestations. This work has led to multiple publications in internationally recognized journals and invitations to present at prestigious conferences such as the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR).

Research Skill

Dr. Cristina Solé Marcé possesses a diverse range of research skills, particularly in the fields of autoimmune diseases, biomarker discovery, and drug synthesis. She has extensive experience in molecular biology techniques, biochemical assays, and analytical chemistry, which she applies to her studies on systemic lupus erythematosus (SLE) and antiphospholipid syndrome. Her expertise includes non-invasive biomarker identification to improve disease monitoring and understanding the mechanisms of action of novel therapeutic agents. With a strong background in synthetic chemistry, she has worked on the enantioselective synthesis of drugs and the development of anticancer compounds. Additionally, she is skilled in experimental design, data analysis, and scientific communication, with multiple publications in high-impact journals and presentations at international conferences such as ACR and EULAR. Her interdisciplinary approach, combining chemistry, biochemistry, and immunology, enables her to contribute significantly to translational research and patient-centered advancements in rheumatology.

Conclusion

Dr. Cristina Solé Marcé is a highly accomplished researcher with an impressive track record in autoimmune disease research, particularly lupus. Her combination of scientific excellence, leadership, international collaboration, and patient engagement makes her a compelling candidate for the Women Researcher Award. Strengthening her funding profile and expanding her research applications could further solidify her impact. Given her current achievements, she is well-deserving of recognition through this award.

Publications Top Noted

  • Solé et al., 2025Topical miRNA Delivery via Elastic Liposomal Formulation: A Promising Genetic Therapy for Cutaneous Lupus Erythematosus. Int. J. Mol. Sci. DOI: 10.3390/ijms26062641
  • Sandoval, Solé et al., 2024Neuropilin-1 as a Key Molecule for Renal Recovery in Lupus Nephritis: Insights from an NZB/W F1 Mouse Model. Int. J. Mol. Sci. DOI: 10.3390/ijms252111364
  • Solé et al., 2024Precise Targeting of Autoantigen-Specific B Cells in Lupus Nephritis with Chimeric Autoantibody Receptor T Cells. Int. J. Mol. Sci. DOI: 10.3390/ijms25084226
  • Solé et al., 2023Small-Extracellular-Vesicle-Derived miRNA Profile Identifies miR-483-3p and miR-326 as Regulators in the Pathogenesis of Antiphospholipid Syndrome (APS). Int. J. Mol. Sci. DOI: 10.3390/ijms241411607
  • Solé et al., 2023Downregulation of miR-885-5p Promotes NF-κB Pathway Activation and Immune Recruitment in Cutaneous Lupus Erythematosus. J. Investig. Dermatol. DOI: 10.1016/j.jid.2022.08.036
  • Solé et al., 2022Humoral and Cellular Response in Convalescent COVID-19 Lupus Patients. Sci. Rep. DOI: 10.1038/s41598-022-17334-5
  • Domingo, Solé et al., 2021Thalidomide Exerts Anti-Inflammatory Effects in Cutaneous Lupus by Inhibiting the IRF4/NF-ҡB and AMPK1/mTOR Pathways. Biomedicines. DOI: 10.3390/biomedicines9121857
  • Domingo, Solé et al., 2020Efficacy of Thalidomide in Discoid Lupus Erythematosus: Insights into the Molecular Mechanisms. Dermatology. DOI: 10.1159/000508672
  • Domingo, Solé et al., 2020MicroRNAs in Several Cutaneous Autoimmune Diseases: Psoriasis, Cutaneous Lupus Erythematosus, and Atopic Dermatitis. Cells. DOI: 10.3390/cells9122656
  • Garcia-Vives, Solé et al., 2020The Urinary Exosomal miRNA Expression Profile is Predictive of Clinical Response in Lupus Nephritis. Int. J. Mol. Sci. DOI: 10.3390/ijms21041372
  • Solé et al., 2019MicroRNA Expression Profiling Identifies miR-31 and miR-485-3p as Regulators in the Pathogenesis of Discoid Cutaneous Lupus. J. Investig. Dermatol. DOI: 10.1016/j.jid.2018.07.026